Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
Partner Therapeutics takes on Sanofi's immunostimulant. Novartis transitions struggling Arzerra for compassionate use only outside the US, with compensation to Genmab, while Shire licenses I.V. immunoglobulin candidate from AB Biosciences.
You may also be interested in...
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
Torrent Pharma has made “substantial progress” with the integration of the acquired Unichem business, turning around key brands and building momentum in field force productivity. Rationalization efforts are expected to drive additional cost savings going forward.
Promising non-traditional antibiotic therapies need a clear path to market to entice investment, US Biomedical Advanced Research and Development Authority official says.